ab109904
MitoTox™ Complex II OXPHOS Activity Assay Kit

For the rapid, sensitive and accurate screening of potential inhibitors of Complex II activity \textit{in vitro}.

This product is for research use only and is not intended for diagnostic use.
# Table of Contents

1. Overview 1  
2. Protocol Summary 3  
3. Precautions 4  
4. Storage and Stability 4  
5. Limitations 5  
6. Materials Supplied 5  
7. Materials Required, Not Supplied 6  
8. Technical Hints 7  
9. Reagent Preparation 8  
10. Sample preparation 9  
11. Assay Procedure – SCREENING ASSAY 10  
13. Data Analysis 16  
14. Typical Data 17  
15. Troubleshooting 18  
16. FAQs 19  
17. Notes 20
1. Overview

MitoTox™ Complex II OXPHOS Activity Assay Kit (ab109904) is designed for testing the direct inhibitory effect of compounds on Complex II activity in only 4 hours. Complex II extracted from the provided bovine heart mitochondria (a rich source of Complex II) is immunocaptured by specific antibodies on the plate. Complex II activity can be observed as decrease in absorbance at OD 600 nm. The intra-assay and inter-assay variation of this assay are both < 15%.

The inhibitory effects of compounds on Complex II activity can be tested in two different ways:
- Screening format (Figure 1, panel A): in this scenario, a maximum of up to 23 compounds can be tested at a single concentration, in triplicate, along with the appropriate blank.
- Dose response (IC$_{50}$) format (Figure 1, panel B): In this scenario, two compounds known to affect Complex II activity can be tested at 11 different data points in triplicate, along the appropriate blanks.

**Figure 1.** Schematic representation of assay set up format. Panel A: assay set up for the screening format with the plate and two 12-well troughs (depicted above and below the plate) provided in the kit. Each color represents a different compound diluted at a single concentration in activity buffer. Panel B: assay set up for the dose response format with the plate and two 12-well troughs (depicted above and below the plate) provided in the kit. Each color gradient represents a compound titration.
Testing for mitochondrial function has become a key aspect of drug discovery. Mitochondria can be affected by drug treatment, resulting into cardio- and hepatotoxic side effects that can lead to drug withdrawal from the market. Therefore, there is increasing emphasis on testing the impact on mitochondria early on in the drug development process to reduce failure rates during preclinical and clinical phases.

OXPHOS Complex II (Succinate-coenzyme Q Reductase, SDH, EC 1.3.5.1) is one of the five complexes involved in oxidative phosphorylation (OXPHOS) in mitochondria. The enzyme complex catalyzes electron transfer from succinate to the electron carrier, ubiquinone, but unlike the other four complexes, it is not a proton pump. The product, ubiquinol, is used by Complex III in the respiratory chain and fumarate is necessary to maintain the Kreb’s/TCA cycle.

Succinate + ubiquinone (Q) → Fumarate + ubiquinol (QH2)

The production of ubiquinol can be monitored by the addition of DCPIP (2,6-dichlorophenolindophenol), which when reduced by ubiquinol recycles the substrate ubiquinone and is transformed from a blue product to a colorless product, leading a decrease in absorbance at OD 600 nm.
2. Protocol Summary

Add detergent-solubilized mitochondria to plate

\[ \downarrow \]

Add Complex II activity solution + test compounds to plate

\[ \downarrow \]

Measure absorbance (OD600 nm) in kinetic mode for 30 minutes at RT*

*For kinetic mode detection, incubation time given in this summary is for guidance only
3. Precautions

Please read these instructions carefully prior to beginning the assay.

- All kit components have been formulated and quality control tested to function successfully as a kit.
- We understand that, occasionally, experimental protocols might need to be modified to meet unique experimental circumstances. However, we cannot guarantee the performance of the product outside the conditions detailed in this protocol booklet.
- Reagents should be treated as possible mutagens and should be handled with care and disposed of properly. Please review the Safety Datasheet (SDS) provided with the product for information on the specific components.
- Observe good laboratory practices. Gloves, lab coat, and protective eyewear should always be worn. Never pipet by mouth. Do not eat, drink or smoke in the laboratory areas.
- All biological materials should be treated as potentially hazardous and handled as such. They should be disposed of in accordance with established safety procedures.

4. Storage and Stability

Store kit at 4°C (store Bovine Heart Mitochondria, Succinate, DCPIP and Ubiquinone 2 at -80°C) in the dark immediately upon receipt. Kit has a storage time of 1 year from receipt, providing components have not been reconstituted.

Refer to list of materials supplied for storage conditions of individual components. Observe the storage conditions for individual prepared components in the Materials Supplied section.

Aliquot components in working volumes before storing at the recommended temperature.
5. Limitations

- Assay kit intended for research use only. Not for use in diagnostic procedures.
- Do not mix or substitute reagents or materials from other kit lots or vendors. Kits are QC tested as a set of components and performance cannot be guaranteed if utilized separately or substituted.

6. Materials Supplied

<table>
<thead>
<tr>
<th>Item</th>
<th>Quantity</th>
<th>Storage temperature (before prep)</th>
<th>Storage temperature (after prep)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20X Buffer</td>
<td>5 mL</td>
<td>4°C</td>
<td>4°C</td>
</tr>
<tr>
<td>Complex II Activity Buffer</td>
<td>25 mL</td>
<td>4°C</td>
<td>4°C</td>
</tr>
<tr>
<td>10X Detergent</td>
<td>1 mL</td>
<td>4°C</td>
<td>4°C</td>
</tr>
<tr>
<td>Bovine Heart Mitochondria</td>
<td>2 x 360 µL</td>
<td>-80°C</td>
<td>-80°C</td>
</tr>
<tr>
<td>DCIP</td>
<td>250 µL</td>
<td>-80°C</td>
<td>-80°C</td>
</tr>
<tr>
<td>Succinate</td>
<td>500 µL</td>
<td>-80°C</td>
<td>-80°C</td>
</tr>
<tr>
<td>Ubiquinone 2</td>
<td>60 µL</td>
<td>-80°C</td>
<td>-80°C</td>
</tr>
<tr>
<td>Pre-coated 96-well microplate</td>
<td>1 unit</td>
<td>4°C</td>
<td>4°C</td>
</tr>
<tr>
<td>12-channel reagent reservoirs</td>
<td>2 units</td>
<td>4°C/RT</td>
<td>N/A</td>
</tr>
</tbody>
</table>
7. Materials Required, Not Supplied

These materials are not included in the kit, but will be required to successfully perform this assay:

- Microplate reader capable of measuring absorbance at OD 600 nm
- Double distilled water (ddH₂O)
- Pipettes and pipette tips, including multi-channel pipette
- Assorted glassware for the preparation of reagents and buffer solutions
- Tubes for the preparation of reagents and buffer solutions
- Disposable single channel reservoirs
- Syringe needle
- (Optional) TTFA (2-thenoyltrifluoroacetone) – Complex II inhibitor: use at 100 mM stock solution (in DMSO)
8. Technical Hints

- This kit is sold based on number of tests. A “test” simply refers to a single assay well. The number of wells that contain sample, control or standard will vary by product. Review the protocol completely to confirm this kit meets your requirements. Please contact our Technical Support staff with any questions.

- Selected components in this kit are supplied in surplus amount to account for additional dilutions, evaporation, or instrumentation settings where higher volumes are required. They should be disposed of in accordance with established safety procedures.

- Avoid foaming or bubbles when mixing or reconstituting components.

- Avoid cross contamination of samples or reagents by changing tips between sample and reagent additions.

- Ensure plates are properly sealed or covered during incubation steps.

- Ensure all reagents and solutions are at the appropriate temperature before starting the assay.

- Make sure all necessary equipment is switched on and set at the appropriate temperature.
9. Reagent Preparation

Briefly centrifuge small vials at low speed prior to opening.

9.1 20X Buffer:
Prepare 1X Buffer by diluting 20X Buffer in ddH₂O: make 100 mL 1X Buffer by combining 5 mL 20X Buffer with 95 mL ddH₂O and mix thoroughly and gently. Label this mixture as Buffer Solution. Equilibrate to room temperature before use. Store 1X Buffer Solution at 4°C.

9.2 Complex II Activity Buffer:
Ready to use as supplied. Equilibrate to room temperature before use. Store at 4°C.

9.3 10X Detergent:
Ready to use as supplied. Thaw on ice. Keep on ice while in use. Store at 4°C.

9.4 Bovine Heart Mitochondria (5.5 mg/mL):
Ready to use as supplied. Thaw on ice. Avoid multiple freeze/thaw cycles. Store at -80°C.

9.5 DCPIP:
Ready to use as supplied. Thaw on ice. Avoid multiple freeze/thaw cycles. Store at -80°C.

9.6 Succinate:
Ready to use as supplied. Thaw on ice. Avoid multiple freeze/thaw cycles. Store at -80°C.

9.7 Ubiquinone 2:
Ready to use as supplied. Thaw on ice. Avoid multiple freeze/thaw cycles. Store at -80°C.

9.8 Pre-coated 96-well microplate:
Ready to use as supplied. Equilibrate to room temperature before use. Store at 4°C.

Δ Note: We do not recommend using the plate more than once as there is risk of contaminating unused wells.

9.9 12-channel reagent reservoirs:
Ready to use as supplied. Store at room temperature. Do not reuse and discard after using.
10. Sample preparation

**General sample information:**
- Always prepare a fresh set of dilutions for every use.
- Do not use compounds that have been diluted in solvent for more than 3-6 months.

**Test Compounds:**
Dissolve test compounds into appropriate solvent. The volume of the compound should not exceed 1.8% of the total volume of the activity solution in which they are diluted for the assay.

Use the following formula to calculate how much you need to add the activity solution to achieve the desired final concentration on the reaction well:

\[
V_{test} = 900 \mu L \times \frac{[Compound]}{[Stock]}
\]

Where:
- \([Compound]\) = desired concentration of test compound in well.
- \([Stock]\) = stock concentration of test compound.
- 900 \(\mu L\) = total volume of Complex II Solution/Compound.

\(\Delta\) **Note:** See Assay Procedure section for more details
11. Assay Procedure – SCREENING ASSAY

- The 96-well microplate provided has been coated with anti-Complex II monoclonal antibody in rows B-G. Rows A and H have been coated with a null capture monoclonal antibody to be used as background controls.
- We recommend using TTFA in the screening procedure as a positive control. TTFA is a well-known inhibitor of Complex II activity. Following the assay procedure, 50% inhibition of Complex II activity is obtained with 20 ± 2 nM TTFA.
- Do not use compounds that have been diluted in solvent for more than 3-6 months.
- The 12-well troughs included in the kit will facilitate assay set up, so that compounds can be mixed with the activity buffer prior to addition on the plate. The first trough will have compounds 1-12, whereas the second trough will have compounds 12-23 (see Figure 1).

11.1 Bovine Heart Mitochondria (BHM) solubilization and plating:

11.1.1 Add 36 µL of Detergent to each of the provided tubes containing bovine heart mitochondria (BHM) (2 x 360 µL at 5.5 mg/mL each).
11.1.2 Mix well by vortexing.
11.1.3 Incubate tube on ice for 30 minutes.
11.1.4 Centrifuge at 25,000 x g for 20 minutes at 4°C in a cold microcentrifuge.
11.1.5 Collect sample supernatant containing solubilized BHM from each tube and pool together (approx. 513 µL). Discard pellets.
11.1.6 Add 20 mL Buffer Solution to the solubilized BHM (~ 513 µL). Mix well by pipetting up and down.
11.1.7 Add 200 µL of BHM (~ 25 µg mitochondria) to each well of the precoated 96-well microplate.
11.1.8 Cover plate and incubate for 2 hours at room temperature.

11.2 Plate washing:

11.2.1 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.
11.2.2 Add 300 µL of Buffer Solution to each well.
11.2.3 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.

11.2.4 Add 300 µL of Buffer Solution to each well.

11.2.5 Cover the plate and leave at room temperature (on the bench) until ready to add compounds.

11.3 Test Compound preparation:

11.3.1 Prepare Complex II Activity Solution immediately prior to use by adding all the content of the Ubiquinone 2 vial (~ 60 µL) + 250 µL DCPIP and 500 µL succinate to 24 mL of Complex II Activity Buffer, Mix well. Label this solution “Complex II Activity Solution”.

11.3.2 Add each compound (up to 23 different compounds) to be tested to each channel of both 12-channel reagent reservoirs. Leave 1 channel (preferably, last channel) for the addition of a solvent only control.

11.3.3 Add Complex II Activity Solution to each channel of both 12-channel reagent reservoirs to a final volume of 900 µL.

11.3.4 Mix contents of each channel by pipetting up and down with a multichannel pipette.

11.4 Test Compound addition to plate:

11.4.1 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.

11.4.2 Using a multi-channel pipette, add 200 µL of Complex II Activity Solution/Compound from each channel of the first 12-channel reagent reservoir to each well in row A, B, C, D.

11.4.3 Using a multi-channel pipette, add 200 µL of Complex II Activity Solution/Compound from each channel of the second 12-channel reagent reservoir to each well in row E, F, G, H.

Δ Note: Any bubbles in the wells should be popped with a fine needle as quickly as possible.
11.5 Measurement:
11.5.1 Measure output immediately at OD 600 nm on a microplate reader in kinetic mode, every minute, for at least 1 hour at room temperature protected from light.

△ Note: Ensure the limit of maximum OD is set read at 1.0 and Kinetic reading reads as Vmax (mOD-units per minute).

The initial OD should be approximately 0.2 OD-units at 600 nm. The reduction of ubiquininone and subsequent reduction of DCPIP is measured as a decrease in absorbance at OD 600 nm. The linear rate is usually seen between 5-10 minutes. After 15 minutes, the rate of reduction in absorbance is declining for the most active samples due lack of substrate – do not calculate the rate after this point.
12. Assay Procedure – DOSE RESPONSE ASSAY

- The 96-well microplate provided has been coated with anti-Complex II monoclonal antibody in rows B-G. Rows A and H have been coated with a null capture monoclonal antibody to be used as background controls.
- We recommend using TTFA in the screening procedure as a positive control. TTFA is a well-known inhibitor of Complex II activity. Following the assay procedure, 50% inhibition of Complex II activity is obtained with 20 ± 2 nM TTFA.
- Do not use compounds that have been diluted in solvent for more than 3-6 months.
- The 12-well troughs included in the kit will facilitate assay set up, so that compounds can be mixed with the activity buffer prior to addition on the plate. The first trough will have dilution series of compound 1, whereas the second trough will have dilution series of compound 2 (see Figure 1).

12.1 Bovine Heart Mitochondria (BHM) solubilization and plating:

12.1.1 Add 36 µL of Detergent to each of the provided tubes containing bovine heart mitochondria (BHM) (2 x 360 µL at 5.5 mg/mL).
12.1.2 Mix well by vortexing.
12.1.3 Incubate tube on ice for 30 minutes.
12.1.4 Centrifuge at 25,000 x g for 20 minutes at 4°C in a cold microcentrifuge.
12.1.5 Collect sample supernatant containing solubilized BHM from each tube and pool together (approx. 513 µL). Discard pellets.
12.1.6 Add 20 mL Buffer Solution to the solubilized BHM (~ 513 µL). Mix well by pipetting up and down.
12.1.7 Add 200 µL of BHM (~ 25 µg mitochondria) to each well of the precoated 96-well microplate.
12.1.8 Cover plate and incubate for 2 hours at room temperature.

12.2 Plate washing:

12.2.1 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.
12.2.2 Add 300 µL of Buffer Solution to each well.
12.2.3 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.
12.2.4 Add 300 µL of Buffer Solution to each well.
12.2.5 Cover the plate and leave at room temperature (on the bench) until ready to add compounds.

12.3 Test Compound preparation:
12.3.1 Prepare Complex II Activity Solution immediately prior to use by adding all the content of the Ubiquinone 2 vial (~ 60 µL) + 250 µL DCPIP and 500 µL succinate to 24 mL of Complex II Activity Buffer, Mix well. Label this solution “Complex II Activity Solution”.
12.3.2 Compound 1 dose response:
12.3.2.1 Add 900 µL of Complex II Activity Solution to channels 2-12 of the first reagent reservoirs.
12.3.2.2 Add Compound 1 to channel 1 of the first reservoir. Add Complex II Activity Solution to a final volume of 900 µL.

\[\text{Note:} \text{ The volume on channel 1 might vary depending on the serial dilutions you are performed. Please take that in consideration when calculating the volume of compound and/or buffer that you need to add to the channel.}\]
12.3.2.3 Starting with channel 1, generate serial dilutions from channel 2 till channel 11.
12.3.2.4 Add only solvent to channel 12 of the first reservoir as a control.
12.3.3 Repeat same procedure described in Step 12.3.2 for compound 2.
12.3.4 Mix contents of each channel by pipetting up and down with a multichannel pipette.

12.4 Test Compound addition to plate:
12.4.1 Empty the wells by turning the plate over and shaking out any remaining liquid. Blot the plate face down on paper towel.
12.4.2 Using a multi-channel pipette, add 200 µL of Complex II Activity Solution/Compound 1 from each channel of the first 12-channel reagent reservoir to each well in row A, B, C, D.
12.4.3 Using a multi-channel pipette, add 200 µL of Complex II Activity Solution/Compound 2 from each channel of the second 12-channel reagent reservoir to each well in row E, F, G, H.
\textbf{△ Note:} Any bubbles in the wells should be popped with a fine needle as quickly as possible.

\textbf{12.5 Measurement:}

12.5.1 Measure output immediately at OD 600 nm on a microplate reader in kinetic mode, every minute, for at least 1 hour at room temperature protected from light.

\textbf{△ Note:} Ensure the limit of maximum OD is set read at 1.0 and Kinetic reading reads as Vmax (mOD-units per minute).

The initial OD should be approximately 0.2 OD-units at 600 nm. The reduction of ubiquininone and subsequent reduction of DCPIP is measured as a decrease in absorbance at OD 600 nm.

The linear rate is usually seen between 5-10 minutes. After 15 minutes, the rate of reduction in absorbance is declining for the most active samples due lack of substrate – do not calculate the rate after this point.
13. Data Analysis

- Use only the linear rate for calculation. To guarantee that \( V_{\text{max}} \) (mOD-units per minute) is calculated in the linear range, confirm that the \( R^2 \) is close to 0.99 for every measurement in the raw graph window.
- Complex II activity is proportional to the decrease in absorbance at OD 600 nm.

13.1 Calculation of activity of Complex II:

13.1.1 Examine the linear rate of decrease in absorbance at OD 600 nm over time.

13.1.2 For all reaction wells, choose two time points (T1 and T2) in the linear phase of the reaction progress curves and obtain the corresponding OD values at those points (OD1 and OD2).

13.1.3 Calculate reaction rate (mOD/min). Most microplate analysis software can perform this function. Alternatively, use the following formula:

\[
\text{Reaction Rate (mOD/min)} = \frac{(\text{OD}_1 - \text{OD}_2)}{(T_1 - T_2)}
\]

13.1.4 Average the triplicate reading for each sample.

13.1.5 Calculate activity of Complex II as follows:

\[
\text{C II activity} = \text{Rate sample} - \text{Rate background (row A/H)}
\]
14. Typical Data

Data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.

**Figure 2.** Typical dose response curve for TTFA (2-thenoyltrifluoracetone). Assay was performed following the Dose Response Assay Procedure using TTFA, a well known Complex II inhibitor. TTFA was prepared in DMSO to generate a 100 mM stock. Starting with a 500 µM final concentration in well (9 µL in channel 1), 1:2 serial dilutions of TTFA were generated.
## 15. Troubleshooting

<table>
<thead>
<tr>
<th>Problem</th>
<th>Reason</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assay not working</strong></td>
<td>Use of ice-cold buffer</td>
<td>Buffers must be at assay temperature</td>
</tr>
<tr>
<td></td>
<td>Plate read at incorrect wavelength</td>
<td>Check the wavelength and filter settings of instrument</td>
</tr>
<tr>
<td></td>
<td>Use of a different microplate</td>
<td>Colorimetric: clear plates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fluorometric: black wells/clear bottom plates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Luminometric: white wells/clear bottom plates</td>
</tr>
<tr>
<td><strong>Assay with erratic readings</strong></td>
<td>Pipetting errors</td>
<td>Avoid pipetting small volumes (&lt; 5 µL) and prepare a master mix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>whenever possible</td>
</tr>
<tr>
<td></td>
<td>Air bubbles formed in well</td>
<td>Pipette gently against the wall of the tubes</td>
</tr>
<tr>
<td><strong>No signal above background in</strong></td>
<td>Inhibitor concentration too high</td>
<td>Reduce concentration of inhibitor</td>
</tr>
<tr>
<td>inhibitor wells**</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>No inhibition seen in test</strong></td>
<td>Compound is not an inhibitor</td>
<td>Use another compound for your test. Use a known inhibitor as</td>
</tr>
<tr>
<td>compound wells**</td>
<td></td>
<td>positive control (TTFA)</td>
</tr>
</tbody>
</table>
16. FAQs

Q. I want to treat my cells with OXPHOS inhibitors and then look at the effect they have in the OXPHOS complexes activity. Can I use this kit?
A. No, we do not recommend this product. If you treat the cells, let’s say, with rotenone, and then isolate the mitochondria from rotenone-treated cells, all the rotenone present in the cells will wash off during the sample preparation procedure and there will no inhibitor present when the assay is performed. The MitoTox™ range has been specifically designed to test normal mitochondria with inhibitor compounds \textit{in vitro}.

Q. Is there a specific pH that the reaction solution should be in order to measure activity? The inhibitor I’m studying is a strong acid with a pH around 2.
A. The assay will not work on an acidic pH; it needs to be at a neutral pH (7-7.4).
You could add your compound and bring the pH back to neutral, but keep in mind that then you will be testing the salt version and the not acid directly in the assay. For example, malonic acid is a known inhibitor of Complex II, as shown in literature: we have tested the effect of potassium and sodium malonate (which is malonic acid after pH has been adjusted with KOH or NaOH, respectively), and have found that malonate (salt form) is able to inhibit activity of Complex II when tested with our assay.

Q. Can I use my own isolated mitochondria?
A. Yes, you can use mitochondria isolated from human or mouse cells for this assay. This is because the antibody used to capture Complex II in the plate recognizes Complex II from these species. We would still recommend to run a control reaction with the provided mitochondria from cow to ensure the assay is working.
17. Notes
Technical Support

Copyright © 2011-2017 Abcam, All Rights Reserved. The Abcam logo is a registered trademark. All information / detail is correct at time of going to print.

Austria
wissenschaftlicherdienst@abcam.com | 019-288-259

France
supportscientifique@abcam.com | 01.46.94.62.96

Germany
wissenschaftlicherdienst@abcam.com | 030-896-779-154

Spain
soportecientifico@abcam.com | 91-114-65-60

Switzerland
technical@abcam.com

UK, EU and ROW
technical@abcam.com | +44(0)1223-696000

Canada
c.ca.technical@abcam.com | 877-749-8807

US and Latin America
us.technical@abcam.com | 888-772-2226

Asia Pacific
hk.technical@abcam.com | (852) 2603-6823

China
cn.technical@abcam.com | 400 921 0189 / +86 21 2070 0500

Japan
technical@abcam.co.jp | +81-(0)3-6231-0940

Singapore
sg.technical@abcam.com | 800 188-5244

Australia
au.technical@abcam.com | +61-(0)3-8652-1450

New Zealand
nz.technical@abcam.com | +64-(0)9-909-7829